Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma

Next Previous
Search
Trial Profile

A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carmustine (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Melphalan (Primary) ; Venetoclax (Primary)
  • Indications Anaplastic large cell lymphoma; B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 14 Dec 2021 Results assessing the safety of the combination of venetoclax plus BEAM followed by ASCT presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 29 Sep 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
    • 29 Sep 2021 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top